Skip to main content

Table 5 Grade 3–4 adverse events occurring in patients

From: The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study

Grade 3–4 adverse events

AG (n = 24), n (%)

FFX (n = 20), n (%)

P value

Peripheral neuropathy

5

0

0.030*

Neutropenia

6

5

0.676

Febrile neutropenia

1

1

0.895

Thrombocytopenia

5

2

0.328

Vomiting

1

3

0.213

Fatigue

2

0

0.552

Diarrhea

2

2

0.848